Merus (NASDAQ:MRUS) Lowered to Hold at BidaskClub

BidaskClub downgraded shares of Merus (NASDAQ:MRUS) from a buy rating to a hold rating in a research report sent to investors on Wednesday, BidAskClub reports.

A number of other analysts have also weighed in on MRUS. Zacks Investment Research upgraded Merus from a hold rating to a buy rating and set a $19.00 target price for the company in a report on Tuesday. Roth Capital began coverage on Merus in a report on Friday, June 28th. They set a buy rating and a $20.00 target price for the company. Four investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has a consensus rating of Buy and an average target price of $23.29.

Merus stock opened at $20.00 on Wednesday. The business has a fifty day moving average of $16.48 and a two-hundred day moving average of $14.80. The firm has a market cap of $455.00 million, a P/E ratio of -10.87 and a beta of 0.23. Merus has a twelve month low of $11.00 and a twelve month high of $20.95.

A number of institutional investors have recently bought and sold shares of the business. Morgan Stanley lifted its holdings in Merus by 3.1% during the second quarter. Morgan Stanley now owns 92,776 shares of the biotechnology company’s stock worth $1,359,000 after buying an additional 2,788 shares during the period. JPMorgan Chase & Co. lifted its holdings in Merus by 63.5% during the second quarter. JPMorgan Chase & Co. now owns 8,722 shares of the biotechnology company’s stock worth $123,000 after buying an additional 3,389 shares during the period. Athanor Capital LP purchased a new stake in shares of Merus during the 2nd quarter valued at $334,000. Granite Investment Partners LLC purchased a new stake in shares of Merus during the 1st quarter valued at $468,000. Finally, Artal Group S.A. lifted its holdings in shares of Merus by 16.7% during the 2nd quarter. Artal Group S.A. now owns 350,000 shares of the biotechnology company’s stock valued at $5,128,000 after purchasing an additional 50,000 shares during the last quarter. Institutional investors own 52.00% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.

Featured Article: What is the Dividend Aristocrat Index?

Analyst Recommendations for Merus (NASDAQ:MRUS)

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.